胃癌治療市場：依分子類型、化療系列和給藥途徑給藥－2023年至2030年全球預測

預計到 2023 年，全球胃癌治療市場將達到 383,116 萬美元，年複合成長率為 6.12%，預計到 2030 年將出現驚人成長，達到 581451 萬美元。

FPNV定位矩陣

FPNV定位矩陣對於評估全球胃癌治療市場至關重要。透過檢驗業務策略和產品滿意度的關鍵指標，我們對供應商進行全面評估，使您能夠根據您的特定需求做出明智的資訊。這種進階分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市佔率分析

市場佔有率分析可以深入了解供應商在特定市場領域的當前地位。比較供應商對總收入、基本客群和其他關鍵指標的貢獻，可以幫助公司更好地了解他們在爭奪市場佔有率時的表現以及面臨的情況。該分析還揭示了特定行業的競爭程度、累積和合併的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細資訊，並分析其在成熟市場的滲透率。

3. 市場多元化：提供有關新產品發布、未開發地區、最新發展和投資的詳細資訊。

4.市場趨勢：全面了解COVID-19、俄羅斯-烏克蘭衝突和高通膨的累積影響。

5.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、法規狀況、專利狀況、製造能力等進行綜合評估。

6. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告回答了以下問題：

1.全球胃癌治療藥物市場規模及預測如何？

2.在預測期內，COVID-19對全球胃癌治療藥物市場的阻礙因素與影響為何？

3.全球胃癌治療藥物市場在預測期內應投資哪些產品/細分市場/用途/領域？

4.貴公司在全球胃癌藥物市場的競爭策略為何？

5.全球胃癌治療市場的技術趨勢和法律規範是什麼？

6.全球胃癌治療藥物市場主要廠商的市佔率為何？

7. 哪些型態和策略性措施被認為適合進入全球胃癌藥物市場？

目錄

第1章 前言

第2章 調查方法

第3章 執行摘要

第4章 市場概況

第5章 市場洞察

• 市場動態
  • 促進因素
    • 隨著肥胖患者和吸菸人口的增加，胃癌發生率呈上升趨勢
    • 轉移性胃癌新治療方法簡介
    • 提高對胃癌狀和原因的認知
  • 抑制因素
    • 嚴格的藥品核准法規和政策
  • 機會
    • 加速胃癌治療藥物研發
    • 生物相似藥在腫瘤學的快速採用
  • 任務
    • 假藥的可用性
• 市場趨勢
• COVID-19 的累積影響
• 俄羅斯-烏克蘭衝突的累積影響
• 高通膨的累積效應
• 波特五力分析
• 價值鍊和關鍵路徑分析
• 法律規範
• 客戶客製化

第6章 胃癌治療藥物市場：依分子類型

• 介紹
• 生物製品
• 低分子

第7章 胃癌治療藥物市場：依化療線分類

• 介紹
• 初次化療
• 第二線化療

第8章 胃癌治療藥物市場：依給藥途徑

• 介紹
• 口服
• 胃腸外的

第9章 北美及南美胃癌治療市場

• 介紹
• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美國

第10章 亞太胃癌治療市場

• 介紹
• 澳洲
• 中國
• 印度
• 印尼
• 日本
• 馬來西亞
• 菲律賓
• 新加坡
• 韓國
• 台灣
• 泰國
• 越南

第11章歐洲、中東和非洲胃癌藥物市場

• 介紹
• 丹麥
• 埃及
• 芬蘭
• 法國
• 德國
• 以色列
• 義大利
• 荷蘭
• 奈及利亞
• 挪威
• 波蘭
• 卡達
• 俄羅斯
• 沙烏地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公國
• 英國

第12章競爭形勢

• FPNV定位矩陣
• 市佔率分析：主要企業
• 競爭情境分析：主要企業

第13章上市公司名單

第14章附錄

• 討論指南
• 關於許可證和定價

The Global Gastric Cancer Drugs Market is forecasted to grow significantly, with a projected USD 3,831.16 million in 2023 at a CAGR of 6.12% and expected to reach a staggering USD 5,814.51 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Gastric Cancer Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Gastric Cancer Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Molecule Type, market is studied across Biologics and Small Molecules. The Small Molecules is projected to witness significant market share during forecast period.

Based on Lines of Chemotherapy, market is studied across First-line Chemotherapy and Second-line Chemotherapy. The Second-line Chemotherapy is projected to witness significant market share during forecast period.

Based on Route of Administration, market is studied across Oral and Parenteral. The Oral is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.74% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Gastric Cancer Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Gastric Cancer Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Gastric Cancer Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Gastric Cancer Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Gastric Cancer Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Gastric Cancer Drugs Market?

6. What is the market share of the leading vendors in the Global Gastric Cancer Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Gastric Cancer Drugs Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Gastric Cancer Drugs Market, by Molecule Type, 2022 vs 2030
• 4.3. Gastric Cancer Drugs Market, by Lines of Chemotherapy, 2022 vs 2030
• 4.4. Gastric Cancer Drugs Market, by Route of Administration, 2022 vs 2030
• 4.5. Gastric Cancer Drugs Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidences of the stomach cancer with the increasing number of obesity cases and smoking population
    • 5.1.1.2. Introduction of novel therapies for metastatic stomach cancer
    • 5.1.1.3. Increase in awareness about the symptoms and causes of gastric cancer
  • 5.1.2. Restraints
    • 5.1.2.1. Stringent regulations and policies for approval of the drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Accelerating research and development activities in the drugs for gastic cancer
    • 5.1.3.2. Rapid adoption of biosimilars in oncology
  • 5.1.4. Challenges
    • 5.1.4.1. Availability of the counterfeit drugs
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Gastric Cancer Drugs Market, by Molecule Type

• 6.1. Introduction
• 6.2. Biologics
• 6.3. Small Molecules

7. Gastric Cancer Drugs Market, by Lines of Chemotherapy

• 7.1. Introduction
• 7.2. First-line Chemotherapy
• 7.3. Second-line Chemotherapy

8. Gastric Cancer Drugs Market, by Route of Administration

• 8.1. Introduction
• 8.2. Oral
• 8.3. Parenteral

9. Americas Gastric Cancer Drugs Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Gastric Cancer Drugs Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Gastric Cancer Drugs Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. FPNV Positioning Matrix
• 12.2. Market Share Analysis, By Key Player
• 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

• 14.1. Discussion Guide
• 14.2. License & Pricing

LIST OF FIGURES

• FIGURE 1. GASTRIC CANCER DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. GASTRIC CANCER DRUGS MARKET SIZE, 2022 VS 2030
• FIGURE 3. GASTRIC CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2022 VS 2030 (%)
• FIGURE 5. GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2022 VS 2030 (%)
• FIGURE 6. GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2030 (%)
• FIGURE 7. GASTRIC CANCER DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 8. GASTRIC CANCER DRUGS MARKET DYNAMICS
• FIGURE 9. GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 15. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 16. GASTRIC CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 17. GASTRIC CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. GASTRIC CANCER DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. GASTRIC CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 5. GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. GASTRIC CANCER DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 8. GASTRIC CANCER DRUGS MARKET SIZE, BY FIRST-LINE CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GASTRIC CANCER DRUGS MARKET SIZE, BY SECOND-LINE CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 11. GASTRIC CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GASTRIC CANCER DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 14. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 17. ARGENTINA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 18. ARGENTINA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 19. ARGENTINA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 20. BRAZIL GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 21. BRAZIL GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 22. BRAZIL GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 23. CANADA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 24. CANADA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 25. CANADA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 26. MEXICO GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 27. MEXICO GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 28. MEXICO GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 29. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 30. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 31. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 32. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 33. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 34. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 35. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 36. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 37. AUSTRALIA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 38. AUSTRALIA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 39. AUSTRALIA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 40. CHINA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 41. CHINA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 42. CHINA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 43. INDIA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 44. INDIA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 45. INDIA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 46. INDONESIA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 47. INDONESIA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 48. INDONESIA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 49. JAPAN GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 50. JAPAN GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 51. JAPAN GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 52. MALAYSIA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 53. MALAYSIA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 54. MALAYSIA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 55. PHILIPPINES GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 56. PHILIPPINES GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 57. PHILIPPINES GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 58. SINGAPORE GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 59. SINGAPORE GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 60. SINGAPORE GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 61. SOUTH KOREA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 62. SOUTH KOREA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 63. SOUTH KOREA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 64. TAIWAN GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 65. TAIWAN GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 66. TAIWAN GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 67. THAILAND GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 68. THAILAND GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 69. THAILAND GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 70. VIETNAM GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 71. VIETNAM GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 72. VIETNAM GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 73. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 74. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 75. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 76. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 77. DENMARK GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 78. DENMARK GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 79. DENMARK GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 80. EGYPT GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 81. EGYPT GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 82. EGYPT GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 83. FINLAND GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 84. FINLAND GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 85. FINLAND GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 86. FRANCE GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 87. FRANCE GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 88. FRANCE GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 89. GERMANY GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 90. GERMANY GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 91. GERMANY GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 92. ISRAEL GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 93. ISRAEL GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 94. ISRAEL GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 95. ITALY GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 96. ITALY GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 97. ITALY GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 98. NETHERLANDS GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 99. NETHERLANDS GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 100. NETHERLANDS GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 101. NIGERIA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 102. NIGERIA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 103. NIGERIA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 104. NORWAY GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 105. NORWAY GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 106. NORWAY GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 107. POLAND GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 108. POLAND GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 109. POLAND GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 110. QATAR GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 111. QATAR GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 112. QATAR GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 113. RUSSIA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 114. RUSSIA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 115. RUSSIA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 116. SAUDI ARABIA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 117. SAUDI ARABIA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 118. SAUDI ARABIA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 119. SOUTH AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 120. SOUTH AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 121. SOUTH AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 122. SPAIN GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 123. SPAIN GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 124. SPAIN GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 125. SWEDEN GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 126. SWEDEN GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 127. SWEDEN GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 128. SWITZERLAND GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SWITZERLAND GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 130. SWITZERLAND GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 131. TURKEY GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 132. TURKEY GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 133. TURKEY GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 134. UNITED ARAB EMIRATES GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 135. UNITED ARAB EMIRATES GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 136. UNITED ARAB EMIRATES GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 137. UNITED KINGDOM GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 138. UNITED KINGDOM GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 139. UNITED KINGDOM GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 140. GASTRIC CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 141. GASTRIC CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 142. GASTRIC CANCER DRUGS MARKET LICENSE & PRICING